Ad26.HPV16
- Generic Name
- Ad26.HPV16
Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix
Phase 1
Terminated
- Conditions
- Human Papillomavirus Infections
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 9
- Registration Number
- NCT03610581
- Locations
- 🇺🇸
Medpharmics, LLC, Metairie, Louisiana, United States
🇺🇸VGR & NOCCR - Knoxville, Knoxville, Tennessee, United States
🇺🇸Clinical Physiology Associates, Fort Myers, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath